Landmark study analyzes scientific productivity and impact of the top 100 PD investigators
June 9, 2011 in OtherIOS Press is pleased to announce the publication of a landmark study in which both traditional and innovative scientometric approaches have been employed to identify the top 100 Parkinson's disease (PD) investigators since 1985 and measure their scientific productivity as well as the impact of their contributions to the field. The article appears today in the inaugural issue of the Journal of Parkinson's Disease.
This milestone analysis has been conducted by Aaron A. Sorensen, a noted expert in the fields of scientometrics and bibliometrics and currently Clinical Research Industry Specialist at GE Healthcare, and David Weedon, a Publishing Consultant based in London, formerly Managing Director of Biology Reports Ltd. While the study employs traditional bibliometric techniques to rank investigators, the authors have utilized innovative metrics to complement traditional tools that do not always give a full picture of the impact of a researcher's work.
"The number of citations an article receives is widely accepted as a measure of its impact," commented Sorensen and Weedon. "There has not, however, been a broad analysis of the PD research literature to assess, in a comprehensive manner, the impact and productivity of the top investigators, which this study aims to provide. It is interesting to note that approximately half the names in the Top 20 for the last decade are names that did not appear in the Top 20 for the last 25 years."
The authors have compiled a list of the 100 most cited PD researchers since 1985. The top 20 researchers identified are:
- Lees, Andrew J, University College London
- Marsden, C David, University College London
- Agid, Yves, Pitié - Salpêtrière University Hospital, Paris
- Lang, Anthony E, Toronto Western Research Institute
- Olanow, C Warren, Mount Sinai School of Medicine, New York, NY
- Brooks, David J, Imperial College London
- Jenner, Peter, King's College London
- Mizuno, Yoshikuni, Juntendo University School of Medicine, Tokyo
- Fahn, Stanley, Columbia University, New York, NY
- Benabid, Alim-Louis, Joseph Fourier University, Grenoble
- Goetz, Christopher G, Rush University Medical Center, Chicago, IL
- Quinn, Niall P, University College London
- Pollak, Pierre, Joseph Fourier University, Grenoble
- Hirsch, Etienne C, Pitié - Salpêtrière University Hospital, Paris
- Koller, William C, University of North Carolina, Chapel Hill, NC
- Lozano, Andres M, University of Toronto
- Riederer, Peter, Universität Wüzburg
- Jankovic, Joseph, Baylor College of Medicine, Houston, TX
- Daniel, Susan E, University College London
- Tanner, Caroline M, The Parkinson's Institute, Sunnyvale, CA
- Lang, Anthony E, Toronto Western Research Institute
- Farrer, Matthew, Mayo Clinic, Jacksonville, FL
- Lees, Andrew J, University College London
- Olanow, C Warren, Mount Sinai School of Medicine, New York, NY
- Singleton, Andrew, National Institute of Aging NIH, Bethesda, MD
- Przedborski, Serge, Columbia University, New York, NY
- Wood, Nicholas W, University College London
- Pollak, Pierre, Joseph Fourier University, Grenoble
- Benabid, Alim-Louis, Joseph Fourier University, Grenoble
- Poewe, Werner, Innsbruck Medical University
- Jankovic, Joseph, Baylor College of Medicine, Houston, TX
- Fahn, Stanley, Columbia University, New York, NY
- Hardy, John, University College London
- Agid, Yves, Pitié - Salpêtrière University Hospital, Paris
- Lozano, Andres M, University of Toronto
- Albanese, Alberto, Universita Cattolica del Sacro Cuore, Milan
- Goetz, Christopher G, Rush University Medical Center, Chicago, IL
- Dawson, Ted M, Johns Hopkins University, Baltimore, MD
- Cookson, Mark R, National Institute on Aging NIH, Bethesda, MD
- Maraganore, Demetrius M, Mayo Clinic Minnesota, Rochester, MN
Parkinson's disease is the second most common neurodegenerative disorder, affecting 1% of the population over the age of 65. It is characterized by loss of brain cells (neurons) from the mid-brain which use the neurotransmitter dopamine to help control voluntary movements.
More information: Because of the importance of this study to the PD community, the Journal of Parkinson's Disease is making it freely available in electronic format at http://iospress.me … fulltext.pdf
Provided by
IOS Press
-
Landmark paper compares scientific productivity and impact of top 100 AD investigators
Mar 09, 2009 |
not rated yet |
0
-
Rasagiline drug might slow Parkinson's
Sep 23, 2009 |
not rated yet |
0
-
New method for measuring Parkinson's disease prevalence reveals sharp increase in Israel
Jun 09, 2011 |
not rated yet |
0
-
Researchers identify genes associated with onset age of Parkinson's disease
Oct 07, 2009 |
not rated yet |
0
-
New animal study shows promise for development of Parkinson's disease drug
Jun 09, 2011 |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (3) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Your brain on 'shrooms: fMRI elucidates neural correlates of psilocybin psychedelic state
Feb 29, 2012 |
4.9 / 5 (42) |
45
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Researcher calls for new approach to regulating probiotics
In today's Nature scientific journal Dr. Gregor Reid, Director of the Canadian R&D Centre for Probiotics at Lawson Health Research Institute and a scientist at Western University, calls for a Category Tree system to be imp ...
Other
8 hours ago |
not rated yet |
1
|
Professor conducting study to determine whether supplements help muscles grow
Nutritional supplements are often associated with athletes and body builders, but a University of Kansas professor is conducting a research project to determine whether they are in fact, effective and if they might be able ...
Other
13 hours ago |
not rated yet |
0
Researchers develop IT solution to help disabled make better wheelchair selections
A Wayne State University researcher has introduced computer technology that makes it easier for people who need wheelchairs to select one that best suits their needs.
Other
May 23, 2012 |
not rated yet |
0
Study shows how patients use Facebook to solicit kidney donations
Loyola University Medical Center researchers are reporting one of the first studies to examine how patients and families are soliciting living kidney donors on Facebook.
Other
May 23, 2012 |
not rated yet |
0
WHO's Chan re-elected for second term
The World Health Organisation on Wednesday re-appointed Margaret Chan as its chief, who declared universal health care as her top priority.
Other
May 23, 2012 |
not rated yet |
0
Amino acid consumption associated with how fast cancer cells divide
For almost a century, researchers have known that cancer cells have peculiar appetites, devouring glucose in ways that normal cells do not. But glucose uptake may tell only part of cancer's metabolic story. Researchers from ...
'Personality genes' may help account for longevity
"It's in their genes" is a common refrain from scientists when asked about factors that allow centenarians to reach age 100 and beyond. Up until now, research has focused on genetic variations that offer a physiological advantage ...
Gene discovery points towards non-hormonal male contraceptive
A new type of male contraceptive could be created thanks to the discovery of a key gene essential for sperm development.
Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.
Brentuximab vedotin effective in large-cell lymphoma
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete ...
Cyber exercise partners help you go the distance: Motivation gains can double
A new study testing the benefits of a virtual exercise partner shows the presence of a moderately more capable cycling partner can significantly boost the motivation by as much as 100 percent ...